Vandetanib First Global Approval

被引：80

作者：

Commander, Helen ^{[1
]}

Whiteside, Glenn ^{[1
]}

Perry, Caroline ^{[2
]}

机构：

[1] Wolters Kluwer Pharma Solut, R&D Insight, Auckland, New Zealand

[2] Adis, Auckland, New Zealand

来源：

DRUGS | 2011年 / 71卷 / 10期

关键词：

PHASE-II; 1ST-LINE TREATMENT; DOUBLE-BLIND; INHIBITOR; ZD6474;

D O I：

10.2165/11595310-000000000-00000

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Vandetanib is an orally active antagonist of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR or HER I or ErbB1) and RET kinase, and is now available in the US for the treatment of metastatic medullary thyroid cancer (MTC). Regulatory submissions for this indication have been filed in the EU and Canada, with clinical development in malignant MTC ongoing in several other countries. Vandetanib is being developed by AstraZeneca, and is also in phase II development for biliary, breast and prostate cancer. Earlier, AstraZeneca withdrew regulatory filings for non-small cell lung cancer (NSCLC) in the US and EU, and later discontinued development. This article summarizes the milestones in the development of vandetanib leading to this first approval in malignant MTC.

引用

页码：1355 / 1365

页数：11

共 21 条

[1] A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer [J].

Blackhall, Fiona H. ;

O'Brien, Mary ;

Schmid, Peter ;

Nicolson, Marianne ;

Taylor, Paul ;

Milenkova, Tsveta ;

Kennedy, Sarah J. ;

Thatcher, Nick .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) :1285-1288

[2]

Boer K, 2007, BREAST CANCER RES TR, V106, pS274

[3]

Broutin S, 2009, 100 ANN M AM ASS CAN

[4]

Carlomagno F, 2002, CANCER RES, V62, P7284

[5]

Cesca M, 2008, 20 EORTC NCI AACR S, V39

[6] Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial [J].

de Boer, Richard H. ;

Arrieta, Oscar ;

Yang, Chih-Hsin ;

Gottfried, Maya ;

Chan, Valorie ;

Raats, Johann ;

de Marinis, Filippo ;

Abratt, Raymond P. ;

Wolf, Juergen ;

Blackhall, Fiona H. ;

Langmuir, Peter ;

Milenkova, Tsveta ;

Read, Jessica ;

Vansteenkiste, Johan F. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) :1067-1074

[7]

Haddad RI, 2008, 44 ANN M AM SOC CLIN

[8] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial [J].

Herbst, Roy S. ;

Sun, Yon ;

Eberhardt, Wilfried E. E. ;

Germonpre, Paul ;

Saijo, Nagahiro ;

Zhou, Caicun ;

Wang, Jie ;

Li, Longyun ;

Kabbinavar, Fairooz ;

Ichinose, Yukito ;

Qin, Shukui ;

Zhang, Li ;

Biesma, Bonne ;

Heymach, John V. ;

Langmuir, Peter ;

Kennedy, Sarah J. ;

Tada, Hiroomi ;

Johnson, Bruce E. .

LANCET ONCOLOGY, 2010, 11 (07) :619-626

[9] Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer [J].

Heymach, John V. ;

Johnson, Bruce E. ;

Prager, Diane ;

Csada, Edit ;

Roubec, Jaromir ;

Pesek, Milos ;

Spasova, Irena ;

Belani, Chandra P. ;

Bodrogi, Istvan ;

Gadgeel, Shirish ;

Kennedy, Sarah J. ;

Hou, Jeannie ;

Herbst, Roy S. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) :4270-4277

[10] Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer [J].

Heymach, John V. ;

Paz-Ares, Luis ;

De Braud, Filippo ;

Sebastian, Martin ;

Stewart, David J. ;

Eberhardt, Wilfried E. E. ;

Ranade, Anantbhushan A. ;

Cohen, Graham ;

Trigo, Jose Manuel ;

Sandler, Alan B. ;

Bonomi, Philip D. ;

Herbst, Roy S. ;

Krebs, Annetta D. ;

Vasselli, James ;

Johnson, Bruce E. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) :5407-5415

← 1 2 3 →